Wolff Wiese Magana LLC Buys 1,644 Shares of Amgen Inc. (NASDAQ:AMGN)

Wolff Wiese Magana LLC boosted its holdings in Amgen Inc. (NASDAQ:AMGN - Free Report) by 17.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 11,285 shares of the medical research company's stock after purchasing an additional 1,644 shares during the period. Amgen comprises 1.9% of Wolff Wiese Magana LLC's holdings, making the stock its 13th largest position. Wolff Wiese Magana LLC's holdings in Amgen were worth $2,941,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of AMGN. State Street Corp lifted its stake in Amgen by 1.2% in the third quarter. State Street Corp now owns 29,317,018 shares of the medical research company's stock valued at $9,446,236,000 after purchasing an additional 345,537 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Amgen by 0.9% in the third quarter. Geode Capital Management LLC now owns 12,122,889 shares of the medical research company's stock valued at $3,893,771,000 after buying an additional 103,851 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Amgen by 2.4% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 10,532,629 shares of the medical research company's stock valued at $3,393,718,000 after buying an additional 251,876 shares during the last quarter. Janus Henderson Group PLC grew its stake in shares of Amgen by 11.7% during the 3rd quarter. Janus Henderson Group PLC now owns 5,143,330 shares of the medical research company's stock worth $1,657,183,000 after acquiring an additional 538,545 shares during the period. Finally, Pathway Financial Advisers LLC increased its holdings in Amgen by 33,125.4% in the 3rd quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company's stock worth $1,437,115,000 after acquiring an additional 4,446,757 shares during the last quarter. Institutional investors own 76.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AMGN. Barclays lifted their target price on shares of Amgen from $300.00 to $315.00 and gave the stock an "equal weight" rating in a research note on Monday, October 7th. William Blair reiterated an "outperform" rating on shares of Amgen in a research note on Tuesday, November 12th. Piper Sandler dropped their target price on Amgen from $344.00 to $310.00 and set an "overweight" rating on the stock in a research report on Thursday, January 2nd. Jefferies Financial Group reiterated a "buy" rating and issued a $380.00 price target on shares of Amgen in a research report on Tuesday, November 12th. Finally, UBS Group decreased their price objective on Amgen from $335.00 to $326.00 and set a "neutral" rating on the stock in a research note on Thursday, October 31st. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Hold" and a consensus target price of $314.91.

Amgen Trading Up 0.7 %

AMGN stock traded up $1.84 during midday trading on Wednesday, hitting $268.94. The company had a trading volume of 3,581,557 shares, compared to its average volume of 3,134,249. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. Amgen Inc. has a 52 week low of $253.30 and a 52 week high of $346.85. The stock's 50 day moving average price is $277.12 and its 200 day moving average price is $308.03. The stock has a market cap of $144.56 billion, a price-to-earnings ratio of 34.44, a PEG ratio of 2.91 and a beta of 0.56.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping the consensus estimate of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The company had revenue of $8.50 billion for the quarter, compared to analysts' expectations of $8.50 billion. During the same period in the prior year, the firm earned $4.96 earnings per share. The firm's revenue for the quarter was up 23.2% on a year-over-year basis. As a group, equities research analysts expect that Amgen Inc. will post 19.53 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be paid a dividend of $2.38 per share. The ex-dividend date of this dividend is Friday, February 14th. This represents a $9.52 annualized dividend and a yield of 3.54%. This is a positive change from Amgen's previous quarterly dividend of $2.25. Amgen's payout ratio is presently 121.90%.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.